InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.760

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$394 Maxigesic Oral Liquid gets first regulatory approval 14 Jul 2021 9:20AM $4.270 $3.760 fallen by 11.94%
$394 Maxigesic IV launches in Germany and Austria 8 Jul 2021 7:30AM $4.250 $3.760 fallen by 11.53%
$394 ASM 2021 Proxy form 8 Jul 2021 7:30AM $4.250 $3.760 fallen by 11.53%
$394 Notice of Annual Meeting of Shareholders 2021 6 Jul 2021 7:45AM $4.200 $3.760 fallen by 10.48%
$394 Application for quotation of securities - AFP 24 Jun 2021 11:18AM $4.200 $3.760 fallen by 10.48%
$394 Appendix 2A 23 Jun 2021 9:02AM $4.200 $3.760 fallen by 10.48%
$394 Capital Change Notice 21 Jun 2021 9:08AM $4.280 $3.760 fallen by 12.15%
$394 FY 2021 AFT Financial Presentation 24 May 2021 7:31AM $4.300 $3.760 fallen by 12.56%
$394 FY2021 Annual Report 24 May 2021 7:31AM $4.300 $3.760 fallen by 12.56%
$394 FY2021 Announcement App 2 24 May 2021 7:30AM $4.300 $3.760 fallen by 12.56%
$394 FY2021 Announcement 24 May 2021 7:30AM $4.300 $3.760 fallen by 12.56%
$394 Appendix 2A 12 May 2021 2:02PM $4.360 $3.760 fallen by 13.76%
$394 AFT extends Maxigesic IV license in South America 5 May 2021 7:44AM $4.350 $3.760 fallen by 13.56%
$394 AFT Pharmaceuticals to announce full year results on Monday 4 May 2021 7:30AM $4.250 $3.760 fallen by 11.53%
$394 Capital change notice - issue of shares 3 May 2021 12:51PM $4.250 $3.760 fallen by 11.53%
$394 AFT licenses Maxigesic IV in the US 28 Apr 2021 7:30AM $3.680 $3.760 risen by 2.17%
$394 Crystawash Extend distribution in UAE, Kuwait, Oman and Ken 12 Apr 2021 8:52AM $3.950 $3.760 fallen by 4.81%
$394 AFT secures new partners in Poland and Greece 7 Apr 2021 7:30AM $4.400 $3.760 fallen by 14.55%
$394 AFT updates earnings guidance 1 Apr 2021 7:30AM $4.400 $3.760 fallen by 14.55%
$394 AFT licenses Pascomer for Europe 17 Mar 2021 9:14AM $4.100 $3.760 fallen by 8.29%
$394 MAXIGESIC IV LICENSED IN EIGHT NEW EUROPEAN MARKETS 5 Mar 2021 7:31AM $3.870 $3.760 fallen by 2.84%
$394 24-hour efficacy for Crystawash Extend Hand Sanitiser 11 Jan 2021 9:30AM $4.710 $3.760 fallen by 20.17%
$394 AFP builds North American momentum 23 Dec 2020 7:30AM $4.230 $3.760 fallen by 11.11%
$394 AFP determination of Anita Baldauf independence 15 Dec 2020 12:43PM $4.380 $3.760 fallen by 14.16%
$394 issue of shares 25 Nov 2020 12:46PM $4.270 $3.760 fallen by 11.94%

201 - 225 of 546 results

Page 9 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.